| Literature DB >> 25505425 |
Livia J De Picker1, Claudia Cornelis1, Wouter Hulstijn2, Glenn Dumont1, Erik Fransen3, Maarten Timmers4, Luc Janssens4, Manuel Morrens5, Bernard G C Sabbe1.
Abstract
OBJECTIVE: To compare sensorimotor performance and learning in stable schizophrenia patients, healthy age- and sex-matched controls and elderly controls on two variations of the rotary pursuit: circle pursuit (true motor learning) and figure pursuit (motor and sequence learning).Entities:
Keywords: aging and cognitive function; learning curve; motor learning; motor skills; procedural learning; rotor pursuit; schizophrenia
Year: 2014 PMID: 25505425 PMCID: PMC4241745 DOI: 10.3389/fpsyt.2014.00165
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Summary of sensorimotor skill studies with Pursuit rotor task in schizophrenia patients.
| Author (year) | Huston and Shakow (1949)( | Goldberg et al. (1993)( | Granholm et al. (1993)( | Clare et al. (1993)( | Schwartz et al. (1996)( | Kern et al. (1997)( | Weickert et al. (2002)( | Gomar et al. (2011)( |
|---|---|---|---|---|---|---|---|---|
| Version | Contact | Contact | Photoelectric | Not specified | Contact | Photoelectric | Not specified | Digital |
| Design | 2 blocks × 5 trials × 10 s | 3 blocks × 5 trials × 20 s | 6 blocks × 4 trials × 20 s | 5 blocks × 6 trials × 20 s | 6 blocks × 4 trials × 20 s | 6 blocks × 4 trials × 20 s | 6 blocks | 6 blocks × 4 trials × 20 s |
| Days | d1 | d1 | d1 | d1–d8 | d1 | d1 | d1 | d1–d8 |
| SZ 122, C 60 | 24 discordant and 7 normal MZ twin pairs | SZ 11, C 11 | SZ 11, C 12 | SZ 40, C 40 (each 20 elderly, 20 young) | SZ 18, C 15 | SZ 35, C 35 | SZ 43, C 22 | |
| SZ age; mean (range) | 31 (17–44) | 38.4 | 42.7 (21–70) | YSZ 33.1 (26–40), ESZ 63.2 (55–70) | 36.7 | Not specified | 46.9 (24–64) | |
| SZ sex M:F | 14:10 | 11:0 | 7:5 | 38:2 | 18:0 | Not specified | 34:9 | |
| RPM | 60 | 30 and 60 | 45 | 30 | ESZ 40.50, EC 48.75, YSZ 47.25, YC 56.25 | SZ 37.2, C 62.7 | Not specified | Not specified |
| Trial 1 matched? | No | No | No | No | Yes | Yes | Not specified | Yes |
| IQ matched? | No | No | No | No | No | No | Yes (subsample | Yes (subsample |
| Absolute performance difference | SZ < C | SZ = C | SZ = C | SZ < C | SZ < C | SZ = C | SZ < C; IQ matched SZ = C | SZ < C; IQ matched SZ = C |
| Learning rate difference | Not specified | Not specified | SZ = C | SZ = C | SZ < C | SZ = C | SZ = C | SZ = C |
SZ, schizophrenia patients; C, controls; ESZ, elderly schizophrenia patients; EC, elderly controls; YSZ, young schizophrenia patients; YC, young controls; RPM, rotations per minute.
Figure 1Circle pursuit task on-screen, gray line indicating pursuit trajectory, not seen by participants. On the right-hand side, performance bars appeared as feedback after each trial.
Figure 2Figure pursuit task on-screen, gray line indicating pursuit trajectory, not seen by participants. On the right-hand side, performance bars appeared as feedback after each trial.
Demographic and baseline assessment results.
| Schizophrenia patients (S) | Young controls (Y) | Elderly participants (E) | |||
|---|---|---|---|---|---|
| 30 | 30 | 30 | Matched | Matched | |
| Age; mean (range) | 36.4 (23–53) | 37.3 (18–52) | 69.2 (65–79) | ||
| Sex M:F | 20:10 | 20:10 | 20:10 | Matched | Matched |
| Education years; mean (SD) | 12.2 (±2.4) | 15.1 (±2.6) | 14.5 (±3.4) | ||
| NLV Premorbid IQ; mean (SD) | 101.30 (±10.29) | 110.07 (±6.39) | 111.73 (±6.43) | ||
| LCT movement time; mean (SD) | 0.36 (±0.15) | 0.27 (±0.12) | 0.40 (±0.13) | ||
| WCST categories completed; median (range) | 3 (0–5) | 5 (0–5) | 3 (0–6) |
NLV, Dutch adult reading test/.
.
Antipsychotic drug prescriptions in schizophrenia patients.
| Antipsychotic drug name | Number of prescriptions | Dose range |
|---|---|---|
| Clozapine | 8 | 50–700 mg/day |
| Amisulpiride | 7 | 200–800 mg/day |
| Haloperidol decanoate | 7 | 75–200 mg/month |
| Quetiapine | 6 | 50–600 mg/day |
| Olanzapine | 3 | 5–20 mg/day |
| Paliperidone | 3 | 3–6 mg/day |
| Paliperidone depot | 3 | 75–200 mg/month |
| Aripiprazole | 2 | 10–30 mg/day |
| Olanzapine depot | 2 | 210–405 mg/month |
| Risperidone depot | 2 | 50 mg/month |
| Clotiapine | 1 | 40 mg/day |
| Flupentixol | 1 | 1 mg/day |
| Bromperidol decanoate | 1 | 125 mg/month |
| Zuclopentixol depot | 1 | 200 mg/month |
| Risperidone | 1 | 4 mg/day |
Results of the GLM repeated measures analyses.
| Figure pursuit | Circle pursuit | ||||
|---|---|---|---|---|---|
| SessionNumber | 285.76 (2, 88) | <0.001** | 173.36 (2, 88) | <0.001** | |
| TrialNumber | 179.77 (7, 83) | <0.001** | 140.82 (1, 89) | <0.001** | |
| SessionNumber*TrialNumber | 4.17 (14, 76) | <0.001** | 13.34 (2, 88) | <0.001** | |
| Group | 31.59 | <0.001** | 30.80 | <0.001** | |
| SessionNumber*TrialNumber*Group | 1.97 (28, 148) | 0.005** | 0.54 (4, 172) | 0.710 | |
| TrialNumber*Group | 2.80 (7, 52) | 0.015* | 0.07 (1, 58) | 0.799 | |
| Group | 7.80 | 0.007** | 6.51 | 0.013* | |
| WCST_cat | Covariate | 19.42 | <0.001** | 9.35 | 0.003** |
| Group | 4.57 | 0.114 | 2.54 | 0.117 | |
| LCT_MT | Covariate | 7.32 | 0.009** | 3.15 | 0.082 |
| Group | 2.98 | 0.090 | 3.03 | 0.087 | |
| Education years | Covariate | 4.97 | 0.030* | 2.18 | 0.146 |
| Group | 1.82 | 0.183 | 1.84 | 0.181 | |
| WCST(1) + LCT_MT(2) | Covariate1 | 16.33 | <0.001** | ||
| Covariate2 | 5.84 | 0.010** | |||
| Group | 0.67 | 0.418 | |||
| Education years (1) + LCT_MT(2) | Covariate1 | 5.48 | 0.023* | ||
| Covariate2 | 8.86 | 0.004** | |||
| Group | 0.17 | 0.685 | |||
| TrialNumber*Group | 3.42 (7, 52) | 0.004** | 0.08 (1, 58) | 0.775 | |
| Group | 85.77 | <0.001** | 43.63 | <0.001** | |
| WCST_cat | Covariate | 9.01 | 0.004** | 6.84 | 0.011* |
| Group | 61.35 | <0.001** | 27.38 | <0.001** | |
| LCT_MT | Covariatee | 5.24 | 0.024* | 0.61 | 0.439 |
| Group | 52.51 | <0.001** | 27.55 | <0.001** | |
| Mean | Y, S, and E groups | ||||
| SessionNumber*Group | 2.51 (4, 172) | 0.043* | 1.59 (4, 172) | 0.179 | |
| Group | 31.59 | <0.001** | 30.80 | <0.001** | |
| Y group – S group | |||||
| SessionNumber*Group | 0.10 (2, 57) | 0.905 | 0.87 (2, 57) | 0.424 | |
| Group | 9.16 | 0.004** | 11.74 | 0.001** | |
| Y group – E group | |||||
| SessionNumber*Group | 3.42 (2, 57) | 0.039* | 3.19 (2, 57) | 0.049* | |
| Group | 83.78 | <0.001** | 70.26 | <0.001** | |
| Cumulative learning gain | Y, S, and E groups | ||||
| SessionNumber*Group | 2.51 (4, 172) | 0.043* | 1.59 (4, 172) | 0.179 | |
| Group | 7.81 | 0.001** | 1.54 | 0.220 | |
| Y group – S group | |||||
| SessionNumber*Group | 0.10 (2, 57) | 0.905 | 0.87 (2, 57) | 0.424 | |
| Group | 1.04 | 0.312 | 1.50 | 0.225 | |
| Y group – E group | |||||
| SessionNumber*Group | 3.42 (2, 57) | 0.039* | 3.19 (2, 57) | 0.049* | |
| Group | 16.23 | <0.001** | 0.269 | 0.107 | |
.
.
.
.
.
.
.
*Significant at the 0.05 level; **significant at the 0.01 level.
Figure 3Figure pursuit accuracy over three sessions and eight trials.
Figure 4Circle pursuit accuracy over three sessions and two trials.
Figure 5Figure pursuit mean accuracy and cumulative learning gain over three sessions.
Figure 6Circle pursuit mean accuracy and cumulative learning gain over three sessions.